Obrixtamig, a DLL3/CD3 IgG-like T-cell engager for SCLC and epNECs. Just out in JCO. Clearly efficacy in these hard-to-treat cancers and larger studies ongoing will hopefully confirm that. ascopubs.org/doi/10.1200/JC…

Register now for #DCLung25 - a one-day, IASLC endorsed lung cancer conference on Saturday, October 4th in Washington DC. Excited to hear Annabelle Gurwitch AnnabelleGurwitch on "Forging New Meaning for QOL IRL in Lung Cancer Treatment" - don't miss it! medstarhealth.org/dclung25

🫁 TODAY IS WORLD LUNG CANCER DAY Lung cancer is the #1 cause of cancer death. 🔹 2.2M+ diagnosed yearly 🔹 1 in 5 U.S. cancer deaths 🔹 Affects young people & non–tobacco users. Anyone with lungs can get lung cancer. #WorldLungCancerDay

Key lung cancer 🫁 milestones to watch in 2025. 🔗 Follow us for latest clinical trials and insights from the world of oncology 👉 clin.larvol.com #LARVOL #LungCancer #WorldLungCancerDay #CancerResearch #Oncology #ClinicalTrials #CancerData #OncologyInsights #WLCD |

Zongertinib (oral TKI) now U.S. FDA approved based off #BeamionLung1 in previously treated metastatic NSCLC w/ HER2+: - 71% ORR w/ 14.1mos mDoR - mPFS 12.4% - ≥Gr 3 AEs in less than 20%. Common AEs includied diarrhea and rash #OncTwitter #MedTwitter

The U.S. FDA granted accelerated approval to the HER2 inhibitor zongertinib for certain adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors harbored mutations in the tyrosine kinase domain of HER2: brnw.ch/21wUMeb

#NEWS: The U.S. FDA has approved our targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced #NSCLC! This is the first treatment of its kind for this patient population. #LungCancer   Learn more: bit.ly/45OuP1N

#NEWS for media: Our targeted cancer therapy has been approved in the U.S. for people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer by the U.S. FDA. #LifeForward #Oncology

#NEWS: Our targeted therapy for HER2 (ERBB2)-mutant advanced #NSCLC was recommended in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®).     Learn more: bit.ly/4mOdlte   #Oncology #NSCLC #LifeForward

So much progress in the treatment of neuroendocrine tumors 💙 The oncology brothers always make for great conversations! Thank you Oncology Brothers Ken Herrmann COR2ED

#NEWS: New data for patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) at #ESMO25.   These advancements have the potential to fulfill patients’ unmet needs.     Learn more: go.boehringer.com/QpvyH #LifeForward #Oncology

#NEWS: New data for HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) at #ESMO25.     These advancements represent the potential for meaningful moments for this community.      Learn more: bit.ly/43oSFQW   #LifeForward #Oncology

Zongertinib in the 1L setting (#BEAMION LUNG-1 cohort 2) presented by Sanjay Popat showed significant, rapid clinical benefit in patients with untreated HER2-mutant NSCLC with an ORR of 77% and a DCR of 96%. Eagerly awaiting read out from the randomized 1L study (#BEAMION

Oncologists treating HER2 lung cancer patients, please memorize one of the most important #ESMO25 takeaways: “Zongertinib for treatment-naive HER2 lung.” Eager to hopefully see a super fast approval via FDA Oncology And payers take note: Zongertinib exquisitely bends your cost

Front-line zongertinib achieved an ORR of 77%, with a CR rate of 8% and a PR rate of 69%, in patients with treatment-naïve advanced HER2-mutated NSCLC. hubs.li/Q03P9S220 #NSCLC #lcsm #ESMO25 | Sanjay Popat

#ESMO25 Zongertinib showing very promising 1L efficacy in Beamion LUNG-1 expertly presented by Sanjay Popat. Phase III 1L study (Beamion LUNG-2) ongoing, comparing zongertinib to SOC and kudos to this team for mandating crossover. Eager to see results. #ESMOAmbassadors

#NANETS25. Tumor DLL3 high (50%+) is a strong biomarker of response to #obrixtamig in epNECs. Large cohort of patients, congrats ⁦Jaume Capdevila⁩ ét al. ⁦NANETS⁩ ⁦Boehringer Ingelheim⁩

#NEWS: Our targeted therapy for HER2-mutant advanced non-small cell lung cancer has received a Commissioner’s National Priority Voucher from the U.S. FDA.   Learn more: bit.ly/3LzbqLv   #LifeForward #Oncology

With routine NGS and IHC guiding diagnosis, clinicians compared real-world T-DXd experience with rising excitement around zongertinib data. ⭐ Explore how these findings may reshape frontline decisions: hubs.li/Q03WYHNg0 #NSCLC

Physicians in The Network are leading the way on new #CancerResearch, including finding ways to make it more accessible. In this interview with OncLive.com, Dr. Martin Dietrich discusses the research into zongertinib as a treatment for HER2 #NSCLC: onclive.com/view/fda-appro…